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To evaluate alternative cervical cancer screening methods, digital colposcopy and collection of cervical exfoliated cells for liquid-based
cytology (LBC) and hybrid capture 2 (HC2) testing were performed among 2562 women aged 15–59 years in three study sites in
the People’s Republic of China (rural Shanxi province, Shenyang city in Liaoning province and Shenzhen city in Guangdong province).
Visual inspection with acetic acid (VIA) was also evaluated independently from colposcopy. A total of 74 cases of histologically
confirmed cervical intraepithelial neoplasia grade 2 or worse (CIN2þ) were identified, and 16 CIN2þ cases were imputed among
unbiopsied women to correct for verification bias. Corrected sensitivity for CIN2þ was 37% for VIA, 54% for colposcopy, 87% for
LBC with a threshold of atypical cells of undetermined significance (LBCXASCUS), 90% for HC2, 84% for LBC using HC2 to triage
ASCUS and 96% for positivity to LBCXASCUS or HC2. For VIA, sensitivity was much lower among women X40 years (12%) than
those aged p39 years (50%). Specificity varied from 77% for positivity to LBCXASCUS or HC2, up to 94% for LBC using HC2 to
triage ASCUS. In conclusion, LBC, HC2 and their combinations performed well, whereas VIA missed a majority of CIN2þ,
particularly in older women. Digital colposcopy performed better than VIA, but still missed nearly half of CIN2þ in this study.
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Important reductions in cervical cancer incidence have been seen
in developed countries; thanks to cytological screening (Peto et al,
2004). However, requirements for well-trained personnel and the
need for repeated visits have made cytological screening expensive
and logistically difficult to implement in low-resource settings
(Kitchener et al, 2006), where more than 80% of cervical cancer
cases worldwide currently occur (Parkin and Bray, 2006).
During the last decade, alternatives to cytological screening have
been evaluated in low-resource settings (Belinson et al, 2001;
Ferreccio et al, 2003; De Vuyst et al, 2005; IARC, 2005; Sarian et al,
2005; Sangwa-Lugoma et al, 2006; Almonte et al, 2007; Pretorius
et al, 2007; Sankaranarayanan et al, 2007). Visual inspection with
acetic acid (VIA) is a low-cost option that allows the possibility of
screening and treatment in one visit (Denny et al, 2005), and has
been shown to significantly reduce cervical cancer mortality in a
large randomised controlled trial (Sankaranarayanan et al, 2007).
Furthermore, shifting of screening towards the detection of human
papillomavirus (HPV), the main cause of cervical cancer, is
increasingly being considered (Denny et al, 2000; Belinson et al,
2001; Sankaranarayanan et al, 2004b; De Vuyst et al, 2005; Sarian
et al, 2005; Cuzick et al, 2006; Almonte et al, 2007; Mayrand et al,
2007).
We, therefore, nested an evaluation of the performance and
variability of various screening approaches among three popula-
tion-based samples of women from the People’s Republic of China
invited to undergo gynaecological examination within the frame-
work of the International Agency for Research on Cancer (IARC)
HPV Prevalence Surveys.
MATERIALS AND METHODS
Study subjects
Between March 2004 and July 2005, the Cancer Institute of the
Chinese Academy of Medical Sciences (CI-CAMS) and the IARC
carried out three population-based surveys of HPV prevalence
among women aged 15–59 years in China, namely in rural Shanxi
Province (Dai et al, 2006); Shenyang City, Liaoning Province (Li
et al, 2006) and Shenzhen City, Guangdong Province (Wu et al,
2007). Complete descriptions of the sample populations including
sociodemographic, sexual and reproductive factors have been
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yreported previously (Dai et al, 2006; Li et al, 2006; Wu et al, 2007).
Participation rates were 56% in Shanxi (Dai et al, 2006), 72% in
Liaoning (Li et al, 2006) and 76% in Guangdong (Wu et al, 2007).
All participants signed an informed consent form according to
the recommendations of the IARC and CI-CAMS ethical review
committees, which approved the study.
Among the 2600 participants that underwent a gynaecological
examination, 28 women with hysterectomy, one with missing VIA
and colposcopy results and nine with missing HC2 results were
excluded, leaving 2562 eligible women (743 from Shanxi, 699 from
Liaoning and 1120 from Guangdong) for the present analysis.
Collection of cervical cells
All participants in our study underwent a gynaecological
examination performed by a gynaecologist. A cytobrush was
inserted into the endocervical canal and rotated gently to collect
cells from the endo- and ectocervix. The brush containing cellular
material was then placed in a vial containing CytoRich transport
media (AutoCyte, Tripath Imaging, Burlington, NC, USA), to be
used to perform both liquid-based cytology (LBC) and HPV
testing.
Human papillomavirus genotyping has been reported previously
(Dai et al, 2006; Li et al, 2006; Wu et al, 2007).
Screening tests
Liquid-based cytology, HC2 and digital colposcopy were per-
formed in all three study sites, completely independently from
each other (i.e., each was performed by a different gynaecologist
who was blinded to all other test results). Visual inspection with
acetic acid was also performed everywhere, but only in Liaoning
and Guangdong was it performed by a different gynaecologist than
digital colposcopy. In Shanxi, it was performed by the same
gynaecologist as colposcopy, and hence was not evaluated
(Table 1).
In Shanxi and Liaoning, there was also an ad hoc evaluation of
an optical device employing fluorescence spectroscopy technology.
It was used to take readings in each quadrant of the cervix of all
women before VIA, with positive diagnoses determined auto-
matically by the device’s algorithm. Fluorescence spectroscopy
showed very poor sensitivity (18.3%) and specificity (79.9%; YL
Qiao, personal communication), and is not formally evaluated in
this report. However, findings from biopsies prompted by
fluorescence spectroscopy-positive examinations were used to
reduce verification bias.
VIA The cervix was inspected with the naked eye using a
speculum and a bright halogen focus lamp 1min after application
of 5% acetic acid. The VIA result was reported by quadrant,
as per the criteria in the IARC manual (Sankaranarayanan and
Wesley, 2003). Visual inspection with acetic acid was classified as
negative when no acetowhite lesions were seen, or when only
ill-defined, scattered or geographic acetowhite lesions away from
the squamocolumnar junction were detected. Visual inspection
with acetic acid was classified as positive when dense, opaque,
well-defined acetowhite lesions touching the squamocolumnar
junction or cervical growths turning acetowhite were seen
(Sankaranarayanan and Wesley, 2003).
Digital colposcopy All women underwent digital colposcopic
assessment (Digital Video Colposcope SLC-2000, Shenzhen Gold-
way Industrial Inc., Shenzhen, China) as a primary screening test,
performed by assessing abnormal areas after application of acetic
acid (Sellors and Sankaranarayanan, 2003). Observations were
recorded by quadrant.
LBC Liquid-based cytology was performed either at CI-CAMS,
Beijing, China (for Shanxi and Liaoning), or the Shenzhen Hospital
of Beijing University, Shenzhen, China (for Guangdong). Slides
were prepared from the CytoRich-preserved specimen according
to the manufacturer’s standard protocol, and results were classified
according to the Bethesda System (Wright et al, 2002). All
abnormal smears as well as 10% of normal smears chosen at
random were reviewed by a second experienced cytologist.
HC2 Second-generation hybrid capture microplate-based HPV
testing (HC2 test; Digene Corporation, Gaithersburg, MD, USA)
was performed in CI-CAMS, using the same samples as for LBC,
according to the manufacturer’s instructions. The test uses an RNA
probe mixture of 13 high-risk HPV types. The manufacturer-
recommended cutoff of 1.0pgml
 1 was used to define samples as
HPV-positive.
Cervical disease assessment
Colposcopy was used during the first screening visit to obtain a
biopsy from the suspicious area of all women with abnormal
findings by VIA, colposcopy and/or fluorescence spectroscopy.
Colposcopy was also subsequently used to obtain biopsies from
all women with low-grade squamous intraepithelial lesions (LSILs)
or worse, or those with HC2-positive atypical squamous cells of
undetermined significance (ASCUS), but without biopsy in the
first visit, when these results became available (approximately one
month later). In the absence of a specific suspicious area, biopsies
were taken from each quadrant of the transformation zone.
Women whose entire squamocolumnar junction could not be seen
upon colposcopy underwent endocervical curettage.
Cervical biopsies were prepared and read by a pathologist at CI-
CAMS, Beijing, China. In this study, cervical abnormalities were
defined as the presence of histologically confirmed cervical
intraepithelial neoplasia grade 2 or worse (CIN2þ). Treatment
of colposcopy-detected lesions was performed according to
local protocols, primarily using loop electrosurgical excision
procedures.
A total of 653 biopsies were obtained, 195 of which were
triggered exclusively by positive findings at fluorescence
Table 1 Description of selected characteristics, screening test positivity
and biopsies taken among study participants by study site
Shanxi Liaoning Guangdong All
N (%) N (%) N (%) N (%)
Total 743 (100) 699 (100) 1120 (100) 2562 (100)
Selected characteristics
Age group (years)
15–29 147 (19.8) 121 (17.3) 348 (31.1) 616 (24.0)
30–39 198 (26.7) 193 (27.6) 384 (34.3) 775 (30.3)
40–49 197 (26.5) 191 (27.3) 295 (26.3) 683 (26.7)
50–59 201 (27.1) 194 (27.8) 93 (8.3) 488 (19.1)
Secondary education 86 (11.6) 317 (45.4) 895 (79.9) 1298 (50.7)
Unmarried 26 (3.5) 76 (10.9) 151 (13.5) 253 (9.9)
41 lifetime sexual partner 129 (17.4) 117 (16.7) 167 (14.9) 413 (16.1)
Pap smear history 68 (9.2) 45 (6.4) 232 (20.7) 345 (13.5)
Screening test outcomes
VIA positive Not assessable 65 (9.3) 142 (12.7) 207 (11.4)
Colposcopy positive 165 (22.2) 105 (15.0) 146 (13.0) 416 (16.2)
LBCXASCUS positive 138 (18.6) 76 (10.9) 225 (20.1) 439 (17.1)
HC2 positive 119 (16.0) 144 (20.6) 155 (13.8) 418 (16.3)
Biopsies taken 301 (40.5) 232 (33.2) 120 (10.7) 653 (25.5)
VIA¼visual inspection with acetic acid; LBCXASCUS¼liquid-based cytology with a
threshold of atypical squamous cells of undetermined significance; HC2¼hybrid
capture 2.
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at one or more of the four screening approaches assessed in this
study. Among these colposcopy-directed biopsies, 74 cases of
CIN2þ (11.3%) were diagnosed (including 51 CIN2, 22 CIN3 and
one cancer).
Statistical analysis
Conventional screening indices, including sensitivity, specificity,
positive predictive value (PPV), negative predictive value (NPV)
and their 95% confidence intervals (CIs) were calculated in two
ways: first, ‘crude’ indices using only histologically confirmed
CIN2þ and assuming that all 1909 women without a biopsy were
histolgically negative; and second, ‘corrected’ indices after
imputation of the missing data (Almonte et al, 2007). Observations
on women with missing biopsies were replaced by pseudo-
observations with each possible value of the missing diagnosis,
and weighted by the estimated probability of having that diagnosis
given the screening test results (Appendix 1). Robust standard
errors were used to account for the uncertainty in the imputation
(White, 1982). The Pearson w
2-test and corresponding P-values
were used to calculate eventual heterogeneity of test performance
by age and centre.
RESULTS
Selected characteristics of the three study populations are
described in Table 1. Overall, 54.3% of women were younger than
40 years old, 50.7% had received secondary education, 9.9% were
unmarried, 16.1% had more than one lifetime sexual partner and
13.5% reported an earlier Pap smear.
Screening test positivity is also shown in Table 1 and, overall,
was 11.4% for VIA, 16.2% for colposcopy, 17.1% for LBC with a
threshold of ASCUS (LBCXASCUS) and 16.3% for HC2. Biopsies
were taken among 40.5, 33.2 and 10.7% of participants in Shanxi,
Liaoning and Guangdong, respectively (Table 1).
Performance of the screening tests
Table 2 reports sensitivity, specificity, PPV and NPV for the
evaluated screening tests, individually (VIA, colposcopy,
LBCXASCUS, and HC2) and in set combinations (LBC using
HC2 to triage ASCUS, and positivity of either LBCXASCUS or
HC2), estimated by both crude and corrected models. The
corrected estimates included an additional 16.2 cases of CIN2þ
imputed among women without biopsies (Appendix 1). Correction
had minimal effect on estimates of sensitivity of HC2 alone, or of
LBCXASCUS or HC2, but sensitivity for VIA, colposcopy,
LBCXASCUS and HC2 triage of ASCUS decreased by 6–7%.
Positivity for LBCXASCUS or HC2 showed the highest sensitivity
(95.5% corrected estimate), followed by HC2 alone (90.4%) and
HC2 triage of ASCUS (84.0%). Corrected estimates of sensitivity
for colposcopy and VIA were 54.1 and 37.1%, respectively.
Corrected estimates of specificity ranged from 77.3% for
LBCXASCUS or HC2, up to 93.8% for HC2 triage of ASCUS.
Visual inspection with acetic acid, colposcopy, LBCXASCUS and
HC2 all showed corrected specificity between 85.1 and 89.4%.
Positive predictive value was highest for HC2 triage of ASCUS
(33.1%), followed by HC2 (19.5%) and LBCXASCUS (17.8%), all
of which showed an NPV of at least 99.4%. Positive predictive
value and NPV were lower for colposcopy (11.7 and 98.1%,
respectively) and VIA (10.0 and 97.8%).
With respect to the 22 CIN3 cases, all were HC2-positive, 21
were LBCXASCUS-positive and 10 were colposcopy-positive. Of
the nine CIN3 cases arising in study sites where VIA was evaluated,
four were VIA-positive. The only case of invasive cancer was an
HC2-positive, but colposcopy-negative, high-grade squamous
intraepithelial neoplasia.
Figure 1 shows the comparison of screening test performance
among women aged 39 years or younger and 40 years or older,
based upon corrected estimates. Visual inspection with acetic acid
was significantly more sensitive in women aged 39 years or
younger (49.9%) than older women (12.2%; w1
2¼7.51; P¼0.006).
Also colposcopy was slightly more sensitive, whereas LBCXAS-
CUS, HC2 and their combinations were slightly less sensitive in
younger than older women, although none of these differences
were statistically significant.
The sensitivity and specificity of different screening tests varied
somewhat across study sites, but no significant heterogeneity
emerged (data not shown). Furthermore, the performance of the
screening tests relative to each other, most notably the relatively
lower sensitivity of visual methods in comparison with LBC, HC2
and their combinations were consistent across the three study sites
(data not shown).
Table 2 Crude and corrected sensitivity, specificity, PPV and NPV for CIN2+, by test
Sensitivity Specificity PPV NPV
Tests Status % 95% CI % 95% CI % 95% CI % 95% CI
VIA Crude 42.9 (27.7–59.0) 89.4 (87.8–90.8) 8.7 (5.2–13.4) 98.5 (97.8–99.0)
Corrected 37.1 (26.4–49.3) 89.4 (87.9–90.8) 10.0 (6.7–14.6) 97.8 (97.1–98.4)
Digital colposcopy Crude 60.8 (48.8–72.0) 85.1 (83.6–86.5) 10.8 (8.0–14.2) 98.6 (98.1–99.1)
Corrected 54.1 (44.6–63.3) 85.1 (83.7–86.5) 11.7 (9.0–15.1) 98.1 (97.5–98.5)
LBCXASCUS Crude 93.2 (84.9–97.8) 85.1 (83.7–86.5) 15.7 (12.4–19.5) 99.8 (99.5–99.9)
Corrected 86.9 (81.1–91.1) 85.4 (84.0–86.7) 17.8 (14.7–21.5) 99.4 (99.2–99.6)
HC2 Crude 90.5 (81.5–96.1) 85.9 (84.5–87.2) 16.0 (12.6–19.9) 99.7 (99.3–99.9)
Corrected 90.4 (83.3–94.7) 86.4 (85.0–87.7) 19.5 (16.3–23.2) 99.6 (99.3–99.8)
HC2 triage of ASCUS Crude 90.5 (81.5–96.1) 93.5 (92.4–94.4) 29.3 (23.5–35.6) 99.7 (99.4–99.9)
Corrected 84.0 (77.4–88.9) 93.8 (92.8–94.7) 33.1 (27.6–39.0) 99.4 (99.1–99.6)
LBCXASCUS or HC2 Crude 95.9 (88.6–99.2) 76.9 (75.2–78.5) 11.0 (8.7–13.7) 99.8 (99.5–100.0)
Corrected 95.5 (90.0–98.1) 77.3 (75.7–78.9) 13.3 (11.1–15.9) 99.8 (99.5–99.9)
PPV¼positive predictive value; NPV¼negative predictive value; CI¼confidence interval; CIN2+¼cervical intraepithelial neoplasia grade 2 or worse; VIA¼visual inspection
with acetic acid; LBCXASCUS¼liquid-based cytology with a threshold of atypical squamous cells of undetermined significance; HC2¼hybrid capture 2.
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In our present evaluation of different cervical cancer screening
approaches in China, LBC, HC2 and their combinations performed
well, whereas VIA missed a majority of CIN2þ, particularly in
older women.
Most cervical screening studies suffer, to a varying extent, from
verification bias, especially due to the reliance on a visual method
(colposcopy) as a gold standard, without the possibility for a
positive result using morphological (cytology) and/or virological
(HPV) methods to trigger disease evaluation in colposcopy-
negative women (Mahe ´ and Gaffikin, 2005). This is a particular
problem for alternative visual methods, such as VIA, the results of
which are closely correlated with those of colposcopy (Pretorius
et al, 2007). In this study, verification bias was minimised through
histological disease assessment being prompted by a positive result
for either VIA, colposcopy or LBC (using HC2 to triage ASCUS).
Furthermore, although no truly random biopsies were obtained,
biopsies triggered by fluorescence spectroscopy, which proved to
be a poor screening test, were used to estimate underlying CIN2þ
in women negative for all the above tests.
Visual inspection with acetic acid is an inexpensive and simple
screening approach that has been widely evaluated, although often
with substantial verification bias (IARC, 2005). In this study, VIA
was by far the least sensitive of the evaluated tests across the three
study sites. Visual inspection with acetic acid sensitivity (37%)
from our study fell into the lower range of earlier estimates (29–
95%) (Belinson et al, 2001; Ferreccio et al, 2003; IARC, 2005; De
Vuyst et al, 2005; Sarian et al, 2005; Sangwa-Lugoma et al, 2006;
Almonte et al, 2007; Pretorius et al, 2007; Sankaranarayanan et al,
2007), even when compared only to those studies with minimal
verification bias (50–71%, Belinson et al, 2001; Sarian et al, 2005;
Sangwa-Lugoma et al, 2006; Almonte et al, 2007), and despite
the fact that VIA was performed exclusively by gynaecologists
rather than nurses (Sangwa-Lugoma et al, 2006). The specificity
of VIA (90%) fared better in relation to the estimates from earlier
studies (62–98%) (Belinson et al, 2001; Ferreccio et al, 2003;
IARC, 2005; De Vuyst et al, 2005; Sarian et al, 2005; Sangwa-
Lugoma et al, 2006; Almonte et al, 2007; Pretorius et al, 2007;
Sankaranarayanan et al, 2007), suggesting that gynaecologists may
have been more cautious to classify a women as VIA-positive in
the present (11%) than in earlier studies (3–53%). Indeed,
acetowhite lesions were classified as positive only when a distinct
pattern was noted, the expected outcome being that the application
of a less conservative criterion for VIA would increase sensitivity,
with a corresponding drop in specificity (Denny et al, 2002;
Sangwa-Lugoma et al, 2006).
An important factor in the relatively poor performance of VIA
in our study was a strong decline in the sensitivity of the test in
women aged 40 years or older. Some earlier studies have reported
VIA sensitivity to be stable with age (Cronje et al, 2001;
Sankaranarayanan et al, 2004a), but they suffered from verification
bias. In a large study in Guanacaste, Costa Rica, the performance of
cervicography, a variant of visual inspection with remote
assessment of photographic images of the cervix, was noted to
decrease substantially with age (Ferreccio et al, 2003). Additional
evidence of the worse performance of VIA at older ages comes
from a large randomised controlled trial in which VIA significantly
prevented cervical cancer incidence and mortality in women aged
30–39 years, but not at older ages (Sankaranarayanan et al, 2007).
These findings would suggest that although VIA may be the only
screening approach practicable in many low-resource settings, it is
most appropriate to invest in screening of women before they are
of an age when the retreat of the transformation zone into the
endocervix renders it invisible to visual methods (Sankaranarayanan
and Wesley, 2003).
Colposcopy performed only moderately well as a primary
screening test in our study, in agreement with suggestions from
recent work (Jeronimo and Schiffman, 2006; Pretorius et al, 2007).
Overall, sensitivity and specificity were only 54 and 85%
respectively, which was similar to that in an earlier large study
in China (Pretorius et al, 2007). Like VIA, colposcopy missed more
than half of all CIN2þ among women aged 40 years or older.
Colposcopy was substantially less sensitive than LBC or HC2, as in
earlier studies with minimal verification bias (Belinson et al, 2001;
Pretorius et al, 2007). The performance of visual methods
appeared similar when analyses were restricted to CIN3.
Using ASCUS as a cutoff, LBC showed a sensitivity of 87% and a
specificity of 85%, which is consistent with that seen in earlier
evaluations (Belinson et al, 2001; Davey et al, 2006; Almonte et al,
2007). Liquid-based cytology was performed in two expert
laboratories, and so its quality should not be considered as
representative of some locally performed conventional cytology.
The sensitivity of conventional cytology has been shown to be
poorer than LBC in some low-resource settings (Ferreccio et al,
2003; Almonte et al, 2007), and often only equivalent to, or even
worse than, that of VIA (Sankaranarayanan et al, 2004b; Sarian
et al, 2005; Sangwa-Lugoma et al, 2006; Almonte et al, 2007).
Hybrid capture 2 sensitivity and specificity estimates were
within the range of those from earlier studies (IARC, 2005; Sarian
et al, 2005; Almonte et al, 2007), and similar to a pooled analysis
including 25 studies (Koliopoulos et al, 2007). The use of HC2 to
triage ASCUS resulted in a slight drop in sensitivity compared with
LBC alone, but with a substantial gain in specificity over LBC or
HC2 alone, so that the PPV (33.1%) was the best of all screening
tests. Allowing either LBCXASCUS or HC2 to determine test
positivity increased the sensitivity, but resulted in a corresponding
drop in specificity.
Strengths of our study included the large number and broad age
range of participants who were drawn from three geographically
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Figure 1 Sensitivity and specificity for different screening tests by age
group. LBCXASCUS¼liquid-based cytology with a threshold of atypical
squamous cells of undetermined significance; HC2¼hybrid capture 2;
VIA¼visual inspection with acetic acid.
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performed independently of each other and according to similar
protocols in the study sites, and an invitation procedure based on
population lists ensured the representativeness of the study
populations. A limitation of this study was the number of women
who were lost to follow-up before a histological confirmation of
abnormal screening findings could be made. As a remedy, we
envisaged a model that corrected for the lack of certain biopsies,
but it is of note that these imputed biopsies were few and had
relatively little impact on the conclusions of this study, which
would not have differed substantially if crude estimates of
sensitivity and specificity had been used.
Given their requirement for specialised infrastructure and
relatively high cost, the potential application of LBC and/or HC2
to low-resource settings remains unclear. Given the robustness of
LBC and HPV samples to both time and temperature, however, our
study suggests the feasibility of sending specimens to centralised
laboratories, which can bring down testing costs through
economies of scale. Both tests can be automated and show good
interlaboratory agreement. However, such an approach would still
require additional visits for diagnostic work-up and treatment of
women with positive tests, which is known to result in
considerable losses to follow-up. The potential advent of a new
rapid and inexpensive HPV DNA test requiring minimal
laboratory infrastructure (Lorincz, 2006) would allow a see and
treat approach similar to that currently possible for VIA, but with a
potentially more accurate test.
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Appendix 1
Number of CIN2+ confirmed and estimated among women with and without biopsies, respectively, by combination of LBC, HC2 and digital colposcopy
results
Women with biopsies Women without biopsies Total CIN2+
LBC HC2 Digital colposcopy N Confirmed CIN2+ N Estimated CIN2+ N %
Normal    172 0 1482 0.0 0.0 0.0
ASCUS   22 0 158 0.0 0.0 0.0
LSIL    9 0 2 0.0 0.0 0.0
HSIL    1 0 0 0.0 0.0 0.0
Normal   + 194 3 68 1.1 4.1 1.5
Normal +   28 1 153 5.5 6.5 3.6
Normal + + 20 1 6 0.3 1.3 5.0
ASCUS   + 23 2 7 0.6 2.6 8.7
ASCUS +   50 10 18 3.6 13.6 20.0
LSIL   + 5 1 0 0.0 1.0 20.0
ASCUS + + 37 8 1 0.2 8.2 21.6
LSIL +   23 6 10 2.6 8.6 26.1
LSIL + + 34 18 3 1.6 19.6 52.9
HSIL + + 17 11 0 0.0 11.0 64.7
HSIL +   17 12 1 0.7 12.7 70.6
HSIL   + 1 1 0 0.0 1.0 100.0
Total 653 74 1909 16.2 90.2 3.5
CIN2+¼cervical intraepithelial neoplasia grade 2 or worse; LBC¼liquid-based cytology; HC2¼hybrid capture 2; ASCUS¼atypical squamous cells of undetermined
significance; LSIL¼low-grade squamous intraepithelial lesion; HSIL¼high-grade squamous intraepithelial lesion.
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